Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 11.16
- Piotroski Score 4.00
- Grade Buy
- Symbol (MDGL)
- Company Madrigal Pharmaceuticals, Inc.
- Price $331.16
- Changes Percentage (3.62%)
- Change $11.58
- Day Low $310.02
- Day High $337.44
- Year High $337.44
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $355.50
- High Stock Price Target $410.00
- Low Stock Price Target $111.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$23.15
- Trailing P/E Ratio -10.55
- Forward P/E Ratio -10.55
- P/E Growth -10.55
- Net Income $-373,630,000
Income Statement
Quarterly
Annual
Latest News of MDGL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Price, News, Quote & History - Yahoo Finance
In the third quarter of 2024, net sales reached $62.2 million for Rezdiffra™. Over 80% of commercial lives are covered, with less than 5% needing a biopsy. A clinical outcomes study for compensated ...
By Yahoo! Finance | 4 days ago -
Is Madrigal Pharmaceuticals, Inc. (MDGL) the Best Guru Stock To Buy Now?
The article discusses the 10 Best Guru Stocks To Buy Now, focusing on Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) as one of the top picks....
By Yahoo! Finance | 1 month ago
